Heather Knight Joins Solventum as Chief Commercial Officer to Drive Growth

Solventum Appoints Heather Knight as Chief Commercial Officer

In an important move to strengthen its leadership team, Solventum (NYSE: SOLV) announced the appointment of Heather Knight as Chief Commercial Officer, set to take effect on November 10, 2025. This newly established position underscores their strategic emphasis on global commercial operations within various segments, including MedSurg, Dental Solutions, and Health Information Systems.

Heather Knight comes with over 30 years of extensive leadership experience in the MedTech field, showcasing a proven track record of driving growth and innovation. Previously, she held the position of Chief Operating Officer at Baxter International, where she was integral in leading global sales and overseeing research development, supply chain management, and the regulatory affairs necessary for sustainable business practices. Knight has a rich background in the sector, having contributed in various capacities at Medtronic, Covidien, Tyco Healthcare, and Kendall. Furthermore, she actively serves on the Board of Directors for Waters Corporation, highlighting her influence and expertise within the industry.

The CEO of Solventum, Bryan Hanson, expressed enthusiasm about Knight's arrival, stating that her appointment is reflective of the company's ambition to build a high-performing organization and solidify its position as a leader in the global MedTech marketplace. By consolidating their go-to-market strategy under Knight's stewardship, Solventum aims to enhance coordination and improve profitability across its operations. Hanson pointed out Knight's extensive sector experience as crucial for driving Solventum’s transformation as it pursues independence and growth as a standalone entity.

Upon accepting her new role, Knight shared her excitement about joining Solventum at this significant juncture, emphasizing her commitment to enhancing commercial productivity and exploring market development opportunities. She notes that Solventum possesses exceptional business units positioned for success within their respective markets and looks forward to collaborating with the team to elevate their performance.

As a part of this strategic realignment, it was also disclosed that Chris Barry, Executive Vice President and Group President of MedSurg, will transition out of the company effective December 31, 2025. Bryan Hanson complemented Barry’s leadership role at Solventum, thanking him for his vital contributions to the organization during his time in the company. He pointed out that Barry’s guidance has been essential in managing their largest business segment and expressed gratitude that he will remain through the year to ensure a seamless transition.

Crucially, this leadership change comes with no immediate impact on Solventum's projected financial guidance, reassuring stakeholders that performance metrics will be reported as expected in early November during the third quarter results.

About Solventum

Solventum is dedicated to enabling smarter, safer healthcare solutions that enhance lives. As a recently restructured entity with a rich heritage of innovation, Solventum strives to deliver groundbreaking advancements at the junction of health, materials, and data science. Their mission focuses on providing solutions that significantly improve patient outcomes while empowering healthcare professionals to operate effectively in their roles. To explore more, visit Solventum.com.

Forward-Looking Statements

The information disclosed in this release contains forward-looking statements related to Solventum’s future performance and operational prospects. These statements come with inherent risks and uncertainties that may result in actual outcomes differing materially from those projected. Factors affecting these projections may include worldwide economic conditions, competitive environments, operational execution risks, and other unforeseen events. A comprehensive list of these factors can be found in Solventum’s periodic filings with the U.S. Securities and Exchange Commission. Solventum does not warrant any obligation to update or revise forward-looking statements unless mandated by applicable law.